ZA962629B - Monoclonal antibodies against HIV-1 and vaccines made thereof. - Google Patents
Monoclonal antibodies against HIV-1 and vaccines made thereof.Info
- Publication number
- ZA962629B ZA962629B ZA9602629A ZA962629A ZA962629B ZA 962629 B ZA962629 B ZA 962629B ZA 9602629 A ZA9602629 A ZA 9602629A ZA 962629 A ZA962629 A ZA 962629A ZA 962629 B ZA962629 B ZA 962629B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibodies
- monoclonal antibodies
- antibodies against
- mixtures
- against hiv
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 241000699802 Cricetulus griseus Species 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
- C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1995/001481 WO1996033219A1 (en) | 1995-04-19 | 1995-04-19 | Monoclonal antibodies against hiv-1 and vaccines made thereof |
CA002218515A CA2218515C (en) | 1995-04-19 | 1995-04-19 | Monoclonal antibodies against hiv-1 and vaccines made thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA962629B true ZA962629B (en) | 1997-10-02 |
Family
ID=25679733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9602629A ZA962629B (en) | 1995-04-19 | 1996-04-02 | Monoclonal antibodies against HIV-1 and vaccines made thereof. |
Country Status (11)
Country | Link |
---|---|
US (1) | US5911989A (es) |
EP (1) | EP0822941B1 (es) |
AT (1) | ATE219105T1 (es) |
AU (1) | AU2308595A (es) |
BR (1) | BR9510575A (es) |
CA (1) | CA2218515C (es) |
DE (1) | DE69527089T2 (es) |
ES (1) | ES2178672T3 (es) |
MX (1) | MX9708008A (es) |
WO (1) | WO1996033219A1 (es) |
ZA (1) | ZA962629B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6866000A (en) * | 1999-08-31 | 2001-03-26 | Asahi Glass Company Limited | Process for producing a vic-dichloro acid fluoride |
EP1418940A4 (en) * | 2000-03-02 | 2006-09-20 | Univ Emory | DNA expression vectors and methods of use |
US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
US20040105871A1 (en) * | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
CN1339319A (zh) * | 2000-08-18 | 2002-03-13 | 清华大学 | 一种治疗艾滋病的药物及其制备方法 |
DE60234018D1 (de) * | 2001-03-08 | 2009-11-26 | Univ Emory | Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
CA2504755C (en) * | 2002-10-11 | 2010-12-14 | University Of Maryland Biotechnology Institute | Carbohydrate-based synthetic vaccines for hiv |
CA2525370A1 (en) * | 2003-05-06 | 2004-11-25 | The Scripps Research Institute | Domain-exchanged binding molecules, methods of use and methods of production |
EP1868651A4 (en) | 2005-04-12 | 2010-10-06 | Univ Duke | METHOD FOR INDUCING ANTIBODIES THAT NEUTRALIZE THE HUMAN IMMUNODEFICIENCY VIRUS |
US20080138351A1 (en) * | 2006-08-02 | 2008-06-12 | United Therapeutics Corporation | Liposome treatment of viral infections |
AU2008239628B2 (en) | 2007-04-13 | 2014-01-30 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
WO2009118658A2 (en) * | 2008-03-26 | 2009-10-01 | University Of Oxford | Endoplasmic reticulum targeting liposomes |
EP2331133A4 (en) * | 2008-09-05 | 2012-09-12 | Univ Duke | ANTILIPID ANTIBODIES |
US20110305700A1 (en) * | 2008-09-05 | 2011-12-15 | Duke University | Anti-lipid antibodies |
US20100093563A1 (en) * | 2008-09-22 | 2010-04-15 | Robert Anthony Williamson | Methods and vectors for display of molecules and displayed molecules and collections |
US20100081575A1 (en) * | 2008-09-22 | 2010-04-01 | Robert Anthony Williamson | Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules |
TR201910848T4 (tr) | 2009-02-13 | 2019-08-21 | Immunomedics Inc | İntraselüler olarak ayrilabi̇len bi̇r bağa sahi̇p i̇mmunokonjugatlar |
WO2010109330A2 (en) | 2009-03-27 | 2010-09-30 | University Of Oxford | Cholesterol level lowering liposomes |
WO2011035205A2 (en) | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
CN107115526A (zh) | 2011-05-02 | 2017-09-01 | 免疫医疗公司 | 用于小体积施用的同种异型选择的抗体的超滤浓缩 |
WO2012170765A2 (en) | 2011-06-10 | 2012-12-13 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
CN109513003A (zh) | 2012-08-14 | 2019-03-26 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
KR20230078823A (ko) | 2012-12-13 | 2023-06-02 | 이뮤노메딕스, 인코오포레이티드 | 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약 |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
WO2015048635A1 (en) | 2013-09-27 | 2015-04-02 | Duke University | Mper-liposome conjugates and uses thereof |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CN112759650A (zh) | 2014-04-03 | 2021-05-07 | Igm生物科学股份有限公司 | 修饰的j链 |
WO2015197919A1 (en) | 2014-06-25 | 2015-12-30 | Glykos Finland Oy | Antibody drug conjugates binding to high-mannose n-glycan |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3313443B9 (en) | 2015-06-25 | 2023-10-04 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
EP3824903A1 (en) | 2015-09-30 | 2021-05-26 | IGM Biosciences Inc. | Binding molecules with modified j-chain |
CN108463472A (zh) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j-链的结合分子 |
WO2017093985A1 (en) | 2015-12-05 | 2017-06-08 | Centre Hospitalier Universitaire Vaudois | Hiv binding agents |
CN118043080A (zh) | 2021-08-13 | 2024-05-14 | 昆山新蕴达生物科技有限公司 | 一种基于微管抑制剂的抗体偶联药物 |
CN117881431A (zh) | 2021-08-24 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
WO2023103854A1 (zh) | 2021-12-09 | 2023-06-15 | 昆山新蕴达生物科技有限公司 | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4761470A (en) * | 1985-12-16 | 1988-08-02 | Merck & Co., Inc. | Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody |
US5087557A (en) * | 1986-06-23 | 1992-02-11 | Genetic Systems Corporation | Human monoclonal antibody to lymphadenopathy-associated virus |
US5245015A (en) * | 1991-04-26 | 1993-09-14 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro |
JPH02502251A (ja) * | 1987-11-13 | 1990-07-26 | ヘルマン カーティンガー | ヒトのモノクローン性抗hiv‐1‐抗体 |
IL101201A0 (en) * | 1991-03-11 | 1992-11-15 | Idec Pharma Corp | Methods for selecting antibody reagents,anti-idiotype antibodies and aids vaccine formulations |
US5516657A (en) * | 1992-05-11 | 1996-05-14 | Cambridge Biotech Corporation | Baculovirus vectors for expression of secretory and membrane-bound proteins |
DE69311764T2 (de) * | 1992-05-14 | 1998-02-05 | Polymun Scient Immunbio Forsch | Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren |
EP0725825B1 (en) * | 1993-09-11 | 2001-02-21 | Polymun Scientific Immunbiologische Forschung GmbH | Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains |
-
1995
- 1995-04-19 CA CA002218515A patent/CA2218515C/en not_active Expired - Fee Related
- 1995-04-19 DE DE69527089T patent/DE69527089T2/de not_active Expired - Lifetime
- 1995-04-19 AU AU23085/95A patent/AU2308595A/en not_active Abandoned
- 1995-04-19 MX MX9708008A patent/MX9708008A/es unknown
- 1995-04-19 WO PCT/EP1995/001481 patent/WO1996033219A1/en active IP Right Grant
- 1995-04-19 ES ES95916676T patent/ES2178672T3/es not_active Expired - Lifetime
- 1995-04-19 AT AT95916676T patent/ATE219105T1/de active
- 1995-04-19 EP EP95916676A patent/EP0822941B1/en not_active Expired - Lifetime
- 1995-04-19 BR BR9510575A patent/BR9510575A/pt not_active Application Discontinuation
- 1995-06-07 US US08/478,536 patent/US5911989A/en not_active Expired - Lifetime
-
1996
- 1996-04-02 ZA ZA9602629A patent/ZA962629B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP0822941B1 (en) | 2002-06-12 |
MX9708008A (es) | 1998-03-31 |
DE69527089T2 (de) | 2003-01-02 |
CA2218515A1 (en) | 1996-10-24 |
CA2218515C (en) | 2008-10-07 |
ATE219105T1 (de) | 2002-06-15 |
WO1996033219A1 (en) | 1996-10-24 |
DE69527089D1 (de) | 2002-07-18 |
EP0822941A1 (en) | 1998-02-11 |
AU2308595A (en) | 1996-11-07 |
BR9510575A (pt) | 1998-12-15 |
ES2178672T3 (es) | 2003-01-01 |
US5911989A (en) | 1999-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA962629B (en) | Monoclonal antibodies against HIV-1 and vaccines made thereof. | |
DE69433013D1 (de) | Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten | |
ATE185351T1 (de) | Ein mit hiv-1-glykoprotein reagierender menschlicher monoklonaler igg-1-antikörper und verwendungsmethode | |
DK0586002T3 (da) | Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho | |
CA2310888A1 (en) | Monoclonal human natural antibodies | |
EP0675904A4 (en) | HUMANE NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE VIRUS FROM HUMAN THAT MAKES THE IMMUNE. | |
ATE231002T1 (de) | Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus | |
DE69626423T2 (de) | Verfahren und zusammensetzung zum rekonformieren multiepitopischer antigene zum anregen einer immunantwort | |
TR200002405T2 (tr) | İnsan CD40' a karşı antikorlar | |
IN2012DN00313A (es) | ||
ES2145004T3 (es) | Derivados de anticuerpos. | |
IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
DK0552296T3 (da) | Monoklonale antistoffer fra mus | |
PT912611E (pt) | Anticorpos monoclonais humanos para o anti-gene de superficie da hepatite b | |
MC2308A1 (fr) | Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine | |
CA2449488A1 (en) | Compositions and methods for treating hyperimmune response in the eye | |
MX2023001776A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
ATE125870T1 (de) | Hiv-spezifische monoklonale antikörper und hybridome zu ihrer herstellung. | |
DE68924983T2 (de) | Anti-idiotyp antikörper induktion eines antitumorenresponses. | |
ES2000615A6 (es) | Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3" | |
Hochman et al. | Monoclonal antibodies to immunogenic lymphoma cell variants displaying impaired neoplastic properties: characterization and applications | |
ATE207119T1 (de) | Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind | |
TH39342A (th) | โมโนโคลนอลแอนติบอดีต่อ hiv-1 และวัคซีนที่สร้างจากมัน | |
UA91182C2 (ru) | Антитело, которое специфично связывается с фактором роста соединительной ткани (ctgf) | |
MX9709636A (es) | Anticuerpos de factor antitisular, injertados en regiones determinadoras de complementariedad, y metodos para su uso. |